Phospho-MCM2 (Ser53) Antibody - #AF8489

Figure 6 CDC7 over-expression promotes lymphoma growth, which is reversed by dequalinium. (A, B) Effect of simurosertib-treated SU-DHL-2 and SU-DHL-10 cells after incubation for 4, 6, and 12 h in vitro. (C, D) Effect of dequalinium-treated SU-DHL-2 and SU-DHL-10 cells after incubation for 4, 6, and 12 h in vitro. (E) Viability of CDC7 over-expression using the cell counting kit-8 (CCK-8); (F) Lymphoma volume of BALB/c mice with CDC7-over-expressing and empty plasmid-transfected SU-DHL-10 cells; (G) Mice weight of BALB/c mice with CDC7-over-expressing and empty plasmid-transfected SU-DHL-10 cells; (H) Lymphoma volume of BALB/c mice implanted with SU-DHL-10 cells given dequalinium or placebo as described; (I) Mice weight of BALB/c mice implanted with SU-DHL-10 cells given dequalinium or placebo; (J) Weight of tumors removed from BALB/c mice implanted with SU-DHL-10 cells receiving dequalinium or placebo; (K) Effect of dequalinium-treated lymphoma from mice; (L) Immunohistochemistry was conducted for lymphoma from mice. Tumors were stained for human Ki-67 and human cleaved caspase-3. Data are means ± standard deviation (SD), *P < 0.05, **P < 0.001 and ***P < 0.0001, n.s., no significants.